Financing channel feed

Ap­n­imed and Sh­iono­gi cre­ate $150M joint ven­ture for sleep ap­nea

Last year
Deals
Pharma

En­gine Bio­sciences bags $27M Se­ries A ex­ten­sion to ad­vance pre­ci­sion med­i­cine plat­form in on­col­o­gy

Last year
R&D

Aq­tu­al rais­es $16M for liq­uid biop­sy test for rheuma­toid arthri­tis based on cell-free DNA plat­form

Last year

Lex­eo Ther­a­peu­tics pen­cils in $113M IPO for car­diac and Alzheimer's gene ther­a­py read­outs in 2024

Last year
Startups
Cell/Gene Tx

Ex­clu­sive: Trail­ing Karuna, Map­Light Ther­a­peu­tics aims to im­prove schiz­o­phre­nia, CNS drugs with $225M Se­ries C

Last year
Startups

Deal flow in­flux: Abing­worth's new $356M fund will help Big Phar­ma ex­pand drug la­bels

Last year
Deals
Pharma

Man­aT Bio, a KRAS biotech from Bert Vo­gel­stein and Catalio, tar­gets $153M with Third Rock part­ner as CEO

Last year
Startups

Triveni Bio launch­es with $92M Se­ries A to fund eczema an­ti­body treat­ment

Last year

Eu­rope’s Sofinno­va rais­es first $200M dig­i­tal med­i­cine fund, look­ing to back over 15 star­tups

Last year

DermBiont rais­es $35.2M Se­ries B to ad­vance two der­ma­to­log­i­cal drugs through PhII

Last year

Or­biMed rais­es $4.3B across three funds to in­vest in biotech com­pa­nies, as well as roy­al­ty deals and Chi­na star­tups

Last year

Ram­part Bio­science rais­es $125M for non-vi­ral gene ther­a­pies

Last year
Startups
Cell/Gene Tx

Aio­los Bio launch­es with $245M Se­ries A, chas­ing one of asth­ma’s hottest tar­gets

Last year
Startups

CAR­GO Ther­a­peu­tics heads to Nas­daq in first CAR-T cell ther­a­py IPO pitch of 2023

Last year
Startups
Cell/Gene Tx

French biotech Abi­vax makes Nas­daq de­but, aim­ing to raise $236M to get PhI­II da­ta in IBD

Last year

Mayo Clin­ic-backed Nu­cle­us Ra­dio­Phar­ma rais­es $56M in Se­ries A to boost CD­MO ser­vices

Last year
Manufacturing

Ved­aBio launch­es with $40M+ in ini­tial fund­ing for CRISPR-based mol­e­c­u­lar de­tec­tion tech­nol­o­gy

Last year
Startups
Diagnostics

Atom Bio­science rais­es $83M in Se­ries D for URAT1 in­hibitor in chron­ic gout treat­ment

Last year
R&D

Bellerophon's board ap­proves liq­ui­da­tion plan, leaves Nas­daq af­ter lay­offs and tri­al fail­ures

Last year
People

BioN­Tech ex­pects up to $950M in Covid vac­cine write-offs af­ter Pfiz­er low­ers ex­pec­ta­tions

Last year
Coronavirus

HHS se­lects in­tranasal vac­cine can­di­dates for Project NextGen, doles out $500M in funds

Last year

#Eu­ro­Bio23: The down­turn, tak­ing risks and the ‘biotech mafia’

Last year
People
Deals

As­tria nabs pre­clin­i­cal OX40 atopic der­mati­tis drug for $15M up­front, prices $64M of­fer­ing

Last year
Deals

Ex­clu­sive: Liq­uid-biop­sy start­up clos­es $17M to fund ovar­i­an can­cer di­ag­nos­tic test

Last year
Diagnostics
First page Previous page 25262728293031 Next page Last page
A service from the Financial Times